Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.
暂无分享,去创建一个
[1] G. Fabbrocini,et al. Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy. , 2018, European journal of cancer.
[2] E. Hulstaert,et al. Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review , 2018, Case Reports in Dermatology.
[3] V. Sibaud. Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.
[4] K. Peris,et al. Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) , 2017, Journal of the American Academy of Dermatology.
[5] G. Jeudy,et al. Anti‐PD1‐induced psoriasis: a study of 21 patients , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Toshiyuki Yamamoto,et al. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. , 2016, Acta dermato-venereologica.
[8] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jilly F. Evans,et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. , 2014, Cellular signalling.
[10] C. Punt,et al. PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer , 2012, Journal of immunotherapy.
[11] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.